Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript
Source: SeekingAlpha
2026-01-06 10:28:15 ET
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression January 6, 2026 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript
Cyclerion Therapeutics Inc.
NASDAQ: CYCN
CYCN Trading
-8.55% G/L:
$1.4175 Last:
17,958 Volume:
$1.43 Open:
CYCN Latest News
CYCN Stock Data
$4,651,497
2,578,931
0.75%
20
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
